Artrex Cream
NDC Package 68354-131-10
Package Information
Artrex (camphor, menthol, and turpentine) cream is temporarily relieves aches and pains of muscles and joints due to arthritis, simple backache, sprains, strains, and sports injuries. This formulation utilizes a cream delivery system. Marketed by Bioved Pharmaceuticals, this product is identified by NDC 68354-131 and is authorized under FDA application M014.
Identification & Billing
- RxCUI: 1551280 - camphor 5 % / menthol 3 % / turpentine oil 10 % Topical Cream
- RxCUI: 1551280 - camphor 50 MG/ML / menthol 30 MG/ML / turpentine 100 MG/ML Topical Cream
- RxCUI: 1551280 - camphor 5 % / menthol 3 % / turpentine 10 % Topical Cream
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68354 - Bioved Pharmaceuticals
- 68354-131 - Artrex
- 68354-131-10 - 10 g in 1 TUBE
- 68354-131 - Artrex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68354-131). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68354-131-10 identifies a specific commercial package of 10 g in 1 tube of Artrex, a human over the counter drug labeled by Bioved Pharmaceuticals. This cream is formulated for topical use and contains camphor (natural); menthol; turpentine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bioved Pharmaceuticals on April 01, 2004. The current certification is valid through December 31, 2026.
How is this Bioved Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68354013110. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.